Trial · NCT03992196
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Procedural dizziness | Injury, poisoning and procedural complications | Rotigotine Final Dose 2 mg/24 h | 1 | 2 | 1 |
| other | Procedural dizziness | Injury, poisoning and procedural complications | Rotigotine Final Dose 3 mg/24 h | 0 | 7 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Headache | Nervous system disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Headache | Nervous system disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Rotigotine Final Dose 2 mg/24 h | 1 | 2 | 1 |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Rotigotine Final Dose 3 mg/24 h | 0 | 7 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 2 mg/24 h | 1 | 2 | 1 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Dermatitis contact | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Dermatitis contact | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Eczema | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Eczema | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Rash papular | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Rash papular | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
| other | Skin irritation | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 2 mg/24 h | 0 | 2 | 0 |
| other | Skin irritation | Skin and subcutaneous tissue disorders | Rotigotine Final Dose 3 mg/24 h | 1 | 7 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03992196/events?page=2